Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

1.970 -0.180 (-8.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kyverna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
Via ACCESSWIRE
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
Via ACCESSWIRE
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
Via ACCESSWIRE
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
KYVERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX
From The Rosen Law Firm PA
Via GlobeNewswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
From Kahn Swick & Foti, LLC
Via Business Wire
Rosen Law Firm Urges Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) INVESTOR ALERT: Investors With Large Losses in Kyverna Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q2 2024
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Why Kyverna Therapeutics Stock Is Sinking
Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. Here's a look at the details: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS